Aligos Therapeutics (ALGS) Stock Price, News & Analysis

Company Overview

Aligos Therapeutics, Inc. is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners. The company’s lead program for chronic hepatitis B (CHB) employs a combination approach to silence viral genes and stimulate immune clearance. In parallel, Aligos is progressing antiviral candidates for respiratory viruses, including coronaviruses and influenza, by targeting key viral enzymes and immune pathways.

Aligos’s clinical development strategy emphasizes combination regimens that may offer functional cures rather than life‐long treatment. Its respiratory virus portfolio includes direct‐acting antivirals targeting viral polymerases, alongside immune modulators intended to enhance host defense mechanisms. By integrating novel chemistries with established antiviral targets, the company aims to deliver differentiated therapies across multiple indications.

With clinical trials conducted in North America and partnerships extending to global research centers, Aligos is focused on generating robust data to support regulatory filings. The management team brings deep experience in antiviral drug development, clinical operations and regulatory strategy, positioning the company to advance its mission of developing innovative solutions for patients living with chronic and acute viral diseases.

Key Stats

• Today's Range: $6.24 to $6.64
• 50-Day Range: $5.97 to $8.74
• 52-Week Range: $4.20 to $13.69
• Volume: 135,565 shs
• Average Volume: 147,735 shs
• Market Capitalization: $39.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.50
• Consensus Rating: Moderate Buy

Aligos Therapeutics Stock Analysis - MarketRank™

Aligos Therapeutics scored higher than 66% of companies evaluated by MarketBeat, and ranked 173rd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.2 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Aligos Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 1 strong buy rating, 3 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Aligos Therapeutics has a consensus price target of $41.50, representing about 545.9% upside from its current price of $6.43.

Amount of Analyst Coverage

Aligos Therapeutics has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aligos Therapeutics are expected to grow in the coming year, from ($7.41) to ($5.48) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aligos Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aligos Therapeutics is -0.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aligos Therapeutics has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.68% of the float of Aligos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aligos Therapeutics has a short interest ratio ("days to cover") of 4.55.

Change versus previous month

Short interest in Aligos Therapeutics has recently decreased by 9.96%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aligos Therapeutics does not currently pay a dividend.

Dividend Growth

Aligos Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Aligos Therapeutics this week, compared to 3 articles on an average week.

Search Interest

4 people have searched for ALGS on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Aligos Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.80% of the stock of Aligos Therapeutics is held by insiders.

Percentage Held by Institutions

60.43% of the stock of Aligos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ALGS Stock Analysis - Frequently Asked Questions

How have ALGS shares performed this year?

Aligos Therapeutics' stock was trading at $9.32 at the beginning of the year. Since then, ALGS shares have decreased by 31.1% and is now trading at $6.4250.

How were Aligos Therapeutics' earnings last quarter?

Aligos Therapeutics, Inc. (NASDAQ:ALGS) announced its quarterly earnings data on Thursday, March, 5th. The company reported ($1.91) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.09) by $0.18. The firm earned $0.17 million during the quarter, compared to the consensus estimate of $0.27 million. Aligos Therapeutics had a negative net margin of 1,106.72% and a negative trailing twelve-month return on equity of 28.16%.

When did Aligos Therapeutics' stock split?

Aligos Therapeutics shares reverse split on Monday, August 19th 2024.The 1-25 reverse split was announced on Thursday, August 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

When did Aligos Therapeutics IPO?

Aligos Therapeutics (ALGS) raised $150 million in an initial public offering (IPO) on Friday, October 16th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager.

How do I buy shares of Aligos Therapeutics?

Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aligos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aligos Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Taiwan Semiconductor Manufacturing (TSM) and Adverum Biotechnologies (ADVM).

Company Calendar

• Last Earnings: 3/05/2026
• Today: 5/06/2026
• Next Earnings (Estimated): 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ALGS
• CIK: 1799448
• Web: www.aligos.com
• Phone: 800-466-6059
• Fax: N/A
• Employees: 90
• Year Founded: 2018

Price Target and Rating

• Average Price Target for Aligos Therapeutics: $41.50
• High Price Target: $50.00
• Low Price Target: $20.00
• Potential Upside/Downside: +545.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): ($8.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$24.19 million
• Net Margins: -1,106.72%
• Pretax Margin: -1,092.36%
• Return on Equity: -28.16%
• Return on Assets: -20.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.90
• Quick Ratio: 3.90

Sales & Book Value

• Annual Sales: $2.19 million
• Price / Sales: 18.16
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.67 per share
• Price / Book: 0.74

Miscellaneous

• Outstanding Shares: 6,190,000
• Free Float: 5,891,000
• Market Cap: $39.77 million
• Optionable: No Data
• Beta: 2.28